Cytokeratin and CDX-2 expression in Barrett's esophagus

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 2, 2008, Pages 132-140

  Van Baal, Jantine W P M ^a   Bozikas, Andreas ^a   Pronk, Rick ^a   Kate, Fibo J W Ten ^b   Milano, Francesca ^a   Rygiel, Agnieszka M ^a   Rosmolen, Wilda D ^a   Peppelenbosch, Maikel P ^c   Bergman, Jacques J G H M ^a   Krishnadath, Kausilia K ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Barrett's esophagus; CDX 2; Cytokeratin

Indexed keywords

CYTOKERATIN 13; CYTOKERATIN 18; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM; STOMACH BIOPSY; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; BIOPSY; CARDIA; ESOPHAGUS; HOMEODOMAIN PROTEINS; HUMANS; KERATIN-13; KERATIN-18; KERATIN-20; KERATIN-8; KERATINS; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 38549169032     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701676575     Document Type: Article

References (47)

1. Koop H. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2004;36:103-9.
2. Triadafilopoulos G. Management of Barrett's esophagus with and without dysplasia. Scand. J. Gastroenterol. Suppl. 2003;237:40-6.
3. Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003;35:112-7.
4. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000;356:2079-85.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
6. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
7. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
8. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
9. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933.
10. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.
11. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005;162:454-60.
12. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10.
13. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
14. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
16. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369-97.
17. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Teijgeman R, Mulder AH, et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 1995;55:1971-6.
18. El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 2001;96:1378-82.
19. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999;30:288-94.
20. Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994;9:63-9.
21. Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003;27:952-9.
22. Phillips RW, Frierson HF Jr, Moskaluk CA. CDX2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-7.
23. Suh E, Chen L, Taylor J, Traber PG. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol 1994;14:7340-51.
24. Freund JN, Domon-Dell C, Kedinger M, Duluc I. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 1998;76:957-69.
25. James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 1994;269:15229-37.
26. Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 1996;16:619-25.
27. Mesquita P, Jonckheere N, Almeida R, Ducourouble MP, Serpa J, Silva E, et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem 2003;278:51549-56.
28. Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, Faiss S, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001;49:73-81.
29. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD, et al. Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 2002;277:31909-17.
30. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 2003;300:813-8.
31. Traber PG, Silberg DG. Intestine-specific gene transcription. Annu Rev Physiol 1996;58:275-97.
32. Mitchelmore C, Troelsen JT, Spodsberg N, Sjostrom H, Noren O. Interaction between the homeodomain proteins Cdx2 and HNF1alpha mediates expression of the lactase-phlorizin hydrolase gene. Biochem J 2000;346:529-35.
33. Fang R, Santiago NA, Olds LC, Sibley E. The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation. Gastroenterology 2000;118:115-27.
34. Krasinski SD, Van Wering HM, Tannemaat MR, Grand RJ. Differential activation of intestinal gene promoters: functional interactions between GATA-5 and HNF-1 alpha. Am J Physiol Gastrointest Liver Physiol 2001;281:G69-84.
35. Taylor JK, Boll W, Levy T, Suh E, Siang S, Mantei N, et al. Comparison of intestinal phospholipase A/lysophospholipase and sucrase-isomaltase genes suggest a common structure for enterocyte-specific promoters. DNA Cell Biol 1997;16:1419-28.
36. Sakaguchi T, Gu X, Golden HM, Suh E, Rhoads DB, Reinecker HC. Cloning of the human claudin-2 5′-flanking region revealed a TATA-less promoter with conserved binding sites in mouse and human for caudal-related homeodomain proteins and hepatocyte nuclear factor-1 alpha. J Biol Chem 2002;277:21361-70.
37. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett 2002;176:47-55.
38. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003;38:14-22.
39. van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 2005;129:1274-81.
40. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 2002;15:611-6.
41. Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 2001;25:87-94.
42. Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004;57:1063-8.
43. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004;17:1282-8.
44. Rugge M, Ingravallo G, Farinati F, Russo VM, Zaninotto G, Alvisi V. Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol 2004;28:834-5; 835 [author reply].
45. Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005;138:924-31.
46. Steininger H, Pfofe DA, Muller H, Haag-Sunjic G, Fratianu V. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005;201:573-7.
47. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689-96.